CD4 and COVID-19: Hyperactivation and subsequent dysfunction of effector T cells during the progression of SARS-CoV-2 infection could also be driven by the decrease in CD4+ regulatory T cells (key players in protection from tissue damage by restraining hyperinflammation) observed in COVID-19 patients, especially in those progressing to severe disease (57, 58).